PROM1 and glioblastoma: The use of CD133 to identify GBM stem cells (GSCs) has remained contraversial (51) due to unreliability of distribution, as CD133 is also expressed on long-term established GBM cell lines and thus, calls into question its specificity as stem cell marker and its prognostic validity in patients.